外周血miR-145表达在食管癌放疗近期疗效评价中的意义

doi:10.3760/cma.j.issn.1673-422X.2017.10.003

摘要/Abstract

摘要： 目的探讨食管癌患者外周血微小RNA145(miR145)表达水平与临床病理特征的关系，及其在放疗近期疗效评价中的意义。方法收集在青岛大学附属医院确诊的单纯行根治放疗的食管癌患者52例，采用反转录聚合酶链反应（RTPCR）方法检测入组患者放疗前血浆miR145的相对表达量，并分析其与基本临床病理特征、放疗近期疗效的相关性。结果在52例食管癌患者中，TNM分期Ⅰ～Ⅱ期患者外周血miR145的相对表达量M(QR)为3.14（1.44），高于Ⅲ～Ⅳ期患者的1.71（0.48），差异具有统计学意义（Z=-3.002，P=0.003），而外周血miR145的相对表达量与患者的年龄（Z=-0.403，P=0.687）、性别（Z=-1.179，P=0.238）、饮酒史（Z=-0.389，P=0.697）无明显相关性。放疗近期疗效评价为完全缓解（CR）、部分缓解（PR）和无缓解（NC）组患者外周血miR145的相对表达量分别为3.27（1.64）、1.83（1.26）和1.40（2.51），差异具有统计学意义（H=6.567，P＝0.038）。结论外周血miR145表达水平与食管癌临床分期有显著相关性，其表达水平与食管癌放疗的近期疗效呈正相关，表达量高提示食管癌放疗的近期疗效较好。

关键词: 食管肿瘤, 放射疗法, 微RNAs, 预后

Abstract: ObjectiveTo investigate the relationship between the expression level of microRNA145 (miR145) in peripheral blood and clinicopathological characteristics of esophageal cancer patients and evaluate its significance in shortterm efficacy of radiotherapy. MethodsA total of 52 patients with esophageal cancer diagnosed in Affiliated Hospital of Qingdao University were collected, and all of the patients received radiotherapy alone. The relative expression level of miR145 in peripheral blood was detected by using the method of reverse transcriptase polymerase chain reaction (RTPCR) before radiotherapy. The correlations between the expression of miR145 and pathological characteristics as well as shortterm efficacy of radiotherapy were analyzed. ResultsIn the 52 patients, the relative expression of miR145 ［M(QR)］ in peripheral blood of clinical stage ⅠⅡ was 3.14 (1.44), higher than that of stage ⅢⅣ ［1.71 (0.48)］, and the difference was statistically significant (Z=-3.002, P=0.003). The expression level of miR145 was not related with the age (Z=-0.403, P=0.687), gender (Z=-1.179, P=0.238) and history of drinking (Z=-0.389, P=0.697). The expression levels of miR145 in complete response (CR), partial response (PR) and no change (NC) groups were 3.27 (1.64), 1.83 (1.26) and 1.40 (2.51), respectively, and the difference was statistically significant (H=6.567, P=0.038). ConclusionThe expression level of miR145 in peripheral blood is significantly correlated with the clinical stage of esophageal cancer. Its expression level is positively correlated with the shortterm efficacy of esophageal cancer radiotherapy. High expression of miR145 shows a better shortterm efficacy of radiotherapy.

Key words: Esophageal neoplasms, Radiotherapy, MicroRNAs, Prognosis

王兆坚，陆海军，丁晓，何信佳. 外周血miR-145表达在食管癌放疗近期疗效评价中的意义[J]. 国际肿瘤学杂志, 2017, 44(10): 731-735.

Wang Zhaojian, Lu Haijun, Ding Xiao, He Xinjia. Significance of miR145 expression in peripheral blood in shortterm efficacy evaluation of radiotherapy for esophageal carcinoma[J]. Journal of International Oncology, 2017, 44(10): 731-735.

参考文献

［1］ Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002［J］. CA Cancer J Clin, 2005, 55(2): 74108. ［2］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［3］ Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers［J］. Mol Cancer, 2007, 6(1): 60. DOI: 10.1186/14764598660. ［4］ LagosQuintanam L, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs［J］. Science, 2001, 294(5543): 853858. DOI: 10.1126/science.1064921. ［5］ Manikandan J, Aarthi JJ, Kumar SD, et al. Oncomirs: the potential role of noncoding microRNAs in understanding cancer［J］. Bioinformation, 2008, 2(8): 330334. ［6］ Ma WJ, Lv GD, Tuersun A, et al. Role of microRNA21 and effect on PTEN in Kazakh′s esophageal squamous cell carcinoma［J］. Mol Biol Rep, 2011, 38(5): 32533260. DOI: 10.1007/s1103301004809. ［7］ Luzna P, Gregar J, Uberall I, et al. Changes of microRNAs192, 196a and 203 correlate with Barrett′s esophagus diagnosis and its progression compared to normal healthy individuals［J］. Diagn Pathol, 2011, 6: 114. DOI: 10.1186/174615966114. ［8］ Kurashige J, Kamohara H, Watanabe M, et al. Serum microRNA21 is a novel biomarker in patients with esophageal squamous cell carcinoma［J］. J Surg Oncol, 2012, 106(2): 188192. DOI: 10.1002/jso.23064. ［9］ Skinner HD, Lee JH, Bhutani MS, et al. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma［J］. Cancer, 2014, 120(23): 36353641. DOI: 10.1002/cncr.28911. ［10］ Mathé EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival［J］. Clin Cancer Res, 2009, 15(19): 61926200. DOI: 10.1158/10780432.CCR091467. ［11］ Fu W, Pang L, Chen Y, et al. The microRNAs as prognostic biomarkers for survival in esophageal cancer: a metaanalysis［J］. ScientificWorldJournal, 2014, 2014: 523979. DOI: 10.1155/2014/523979. ［12］ Zhang BJ, Gong HY, Zheng F, et al. Upregulation of miR335 predicts a favorable prognosis in esophageal squamous cell carcinoma［J］. Int J Clin Exp Pathol, 2014, 7(9): 62136218. ［13］中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)［J］. 中华放射肿瘤学杂志, 2010, 19(3): 179180. DOI: 10.3760/cma.j.issn.10044221.2010.03.001. ［14］万钧, 韩春, 刘惠明. 食管癌的放射治疗(修订版)［M］ . 北京: 原子能出版社, 2006: 7072. ［15］ Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14［J］. Cell, 1993, 75(5): 843854. ［16］ Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function［J］. Cell, 2004, 116(2): 281297. ［17］ AlvarezGarcia I, Miska EA. MicroRNA functions in animal development and human disease［J］. Development, 2005, 132(21): 46534662. DOI: 10.1242/dev.02073. ［18］ Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets［J］. Cell, 2005, 120(1): 1520. DOI: 10.1016/j.cell.2004.12.035. ［19］ Christodoulou F, Raible F, Tomer R, et al. Ancient animal microRNAs and the evolution of tissue identity［J］. Nature, 2010, 463(7284): 10841088. DOI: 10.1038/nature08744. ［20］ Sakai NS, SamiaAly E, Barbera M, et al. A review of the current understanding and clinical utility of miRNAs in esophageal cancer［J］. Semin Cancer Biol, 2013, 23(6 Pt B): 512521. DOI: 10.1016/j.semcancer.2013.08.005. ［21］ Zhang CN, Wang C, Chen X, et al. Expression profile of MicroRNAs in serum: a fingerprint for esophageal squamous cell carcinoma［J］. Clin Chem, 2010, 56(12): 18711879. DOI: 10.1373/clinchem.2010.147553. ［22］ Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of microRNAs in human esophageal squamous cell carcinoma using RTPCR［J］. Med Mol Morphol, 2009, 42(2): 102109. DOI: 10.1007/s0079500904431. ［23］ Chen ZL, Zhao XH, Wang JW, et al. microRNA92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via Ecadherin［J］. J Biol Chem, 2011, 286(12): 1072510734. DOI: 10.1074/jbc.M110.165654. ［24］ Zhang J, Guo H, Zhang H, et al. Putative tumor suppressor miR145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene［J］. Cancer, 2011, 117(1): 8695. DOI: 10.1002/cncr.25522. ［25］ Chen Z, Zeng H, Guo Y, et al. miRNA145 inhibits nonsmall cell lung cancer cell proliferation by targeting cMyc［J］. J Exp Clin Cancer Res, 2010, 29: 151. DOI: 10.1186/1756996629151. ［26］ Xu Q, Liu LZ, Qian X, et al. MiR145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis［J］. Nucleic Acids Res, 2012, 40(2): 761774. DOI: 10.1093/nar/gkr730. ［27］ Ye C, Sun NX, Ma Y, et al. MicroRNA145 contributes to enhancing radiosensitivity of cervical cancer cells［J］. FEBS Lett, 2015, 589(6): 702709. DOI: 10.1016/j.febslet.2015.01.037. ［28］ Drebber U, Lay M, Wedemeyer I, et al. Altered levels of the oncomicroRNA21 and the tumorsupressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy［J］. Int J Oncol, 2011, 39(2): 409415. DOI: 10.3892/ijo.2011.1036. ［29］ Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection［J］. Proc Natl Acad Sci USA, 2008, 105(30): 1051310518. DOI: 10.1073/pnas.0804549105. ［30］ Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases［J］. Cell Res, 2008, 18(10): 9971006. DOI: 10.1038/cr.2008.282. ［31］ Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases［J］. RNA Biol, 2012, 9(6): 850859. DOI: 10.4161/rna.20378. ［32］ Nugent M, Miller N, Kerin MJ. Circulating miR34a levels are reduced in colorectal cancer［J］. J Surg Oncol, 2012, 106(8): 947952. DOI: 10.1002/jso.23174. ［33］ Schetter AJ, Okayama H, Harris CC. The role of microRNA in colorectal cancer［J］. Cancer J, 2012, 18(3): 244252. DOI: 10.1097/PPO.0b013e318258b78f.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[6]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[7]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[8]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[9]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[15]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.